Search results
Results from the WOW.Com Content Network
The drugmaker will pay $21 per Fusion share, a premium of more than 97% to the U.S.-listed company's closing price on Monday. AstraZeneca bets on new cancer treatments with $2 billion Fusion ...
Fusion Pharmaceuticals Inc. (FUSN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Even if it's not a huge purchase, we think it was good to see that Steven Gannon, the Independent Director of Fusion... Insider Buying: The Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Independent ...
That same month, the firm also announced the acquisition of Fusion Pharmaceuticals Inc for $2 billion in cash. [ 100 ] In July 2024, National Institute for Health and Care Excellence (Nice) blocked the National Health Service (NHS) from providing Enhertu , an innovative treatment for advanced HER2-low breast cancer, due to AstraZeneca and ...
J. Michael Pearson (born 1959) is a Canadian American [1] pharmaceutical company executive. He is the former chairman and CEO of Valeant Pharmaceuticals International [2] [3] after being ousted in the aftermath of a report on pharmaceutical pricing published by Citron Research in April 2016.
Valeant Pharmaceuticals: Allergan, Inc: 53.3 69 Valeant raised its unsolicited offer for Allergan a second time, to $53.3 billion, increasing the cash portion of the bid in an effort to win the backing of the company, with the cash-and-stock portion of the bid valuing each Allergan share at $179.25. [26] 16 2014 Valeant Pharmaceuticals ...
For premium support please call: 800-290-4726 more ways to reach us
Vertex Pharmaceuticals claimed in a press release that the medication can be used for many types of moderate-to-severe acute pain and has shown no evidence that it is addictive, like opioids.